Stocksigma LogoStocksigma Logo

Remus Pharmaceuticals H1 FY27 Consolidated Revenue Up 53% YoY; Declares Interim Dividend

Remus Pharmaceuticals posted strong H1 FY27 consolidated financial results, with revenue from operations surging 53.45% YoY to ₹614.12 crore compared to

Remus Pharmaceuticals H1 FY27 Consolidated Revenue Up 53% YoY; Declares Interim Dividend

Remus Pharmaceuticals Ltd · Outcome · 03 Nov 2026, 9:28 pm

Remus Pharmaceuticals H1 FY27 Consolidated Revenue Up 53% YoY; Declares Interim Dividend Remus Pharmaceuticals posted strong H1 FY27 consolidated financial results, with revenue from operations surging 53.45% YoY to ₹614.12 crore compared to ₹400.20 crore in H1 FY26. Consolidated EBITDA rose 11.22% YoY to ₹29.93 crore, while PAT grew 14.22% YoY to ₹24.66 crore, despite initial setup and operating cost drags from new subsidiaries. The board approved a first interim dividend of ₹1.00 per equity share (face value ₹10) for FY 2026-27, with the record date set for 7th Nov'26.

Original exchange filing (PDF)

More announcements from Remus Pharmaceuticals Ltd

All Remus Pharmaceuticals Ltd announcements